XGN Exagen

Exagen Inc. to Participate in the Canaccord Genuity 44th Annual Growth Conference

Exagen Inc. to Participate in the Canaccord Genuity 44th Annual Growth Conference

CARLSBAD, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity 44th Annual Growth Conference, which takes place August 13-15, 2024, at the InterContinental Boston Hotel in Boston, MA. John Aballi, Exagen’s President and Chief Executive Officer will participate in a fireside chat on Wednesday, August 14th, at 2:30 PM ET. Interested parties may access the webcast of the presentation using a link on Exagen’s website at .

About Exagen Inc.

Exagen is a leading provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision making with the goal of improving patients’ clinical outcomes. Exagen is located in San Diego County, California.

For more information, please visit or follow on X (formerly known as Twitter).

Contact:

Ryan Douglas

Exagen Inc.



760.560.1525



EN
02/08/2024

Underlying

XGNExagen

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Exagen

 PRESS RELEASE
Free
XGN EXAGEN

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results Record full-year total revenue and AVISE® CTD average selling price New biomarkers and sales force expansion drove over 11% full-year test volume growth CARLSBAD, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today reported financial results for the fourth quarter and full year ended December 31, 2025, and recent business highlights.      Three Months Ended December 31, Year Ended December 31, 2025 2025(in thousands, except ASP data) Revenue$16,631  $6...

5h / 44m 1 EN
 PRESS RELEASE
Free
XGN EXAGEN

Exagen Inc. to Participate in Upcoming Investor Conferences

Exagen Inc. to Participate in Upcoming Investor Conferences CARLSBAD, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following investor conferences: KeyBank Capital Markets Healthcare Forum - Virtual Date: March 17, 2026 Participation: Investor meetings and fireside chat at 3:00 p.m. ET Roth Capital Conference – Laguna Niguel, CA Date: March 23, 2026 Participation: Investor meetings About Exagen Inc. Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune ...

March 3, 2026 1 EN
 PRESS RELEASE
Free
XGN EXAGEN

Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Re...

Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026 CARLSBAD, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended December 31, 2025, before the market opens on Tuesday, March 10, 2026. John Aballi, President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company’s results at 8:30 a.m. ET (5:30 a.m. PT). Conference Call & Webcast: U.S. dial-in: 877-407-0890Inter...

February 24, 2026 1 EN
 PRESS RELEASE
Free
XGN EXAGEN

Exagen Inc. Announces Select Preliminary 2025 Financial Results

Exagen Inc. Announces Select Preliminary 2025 Financial Results CARLSBAD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced select preliminary unaudited financial results for the fourth quarter and year ended December 31, 2025, in line with prior financial guidance. Select Preliminary Unaudited 2025 Results  Revenue  Three Months EndedDecember 31, 2025 Twelve Months EndedDecember 31, 2025Total Revenue$16M to $17M $66M to $67MYear-Over-Year Growth17% to 24% 19% to 20%  Other  Twelve Months EndedDecember 31, 2025...

January 11, 2026 1 EN
 PRESS RELEASE
Free
XGN EXAGEN

Exagen Inc. to Participate in Fourth Quarter Investor Conferences

Exagen Inc. to Participate in Fourth Quarter Investor Conferences CARLSBAD, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following upcoming investor conferences: 16th Annual Craig-Hallum Alpha Select Conference Date: November 18, 2025 Location: Sheraton New York Times Square Hotel Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum Date: November 20, 2025 Location: Westin NY Grand Central - 212 E 42nd Street New York, NY 10017 About Exagen...

November 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch